Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

Stopped The radioligands to be evaluated showed acceptable safety but limited benefit in metastatic prostate cancer

Conditions

• Prostate Cancer

Interventions

• DRUG: AAA602
• DRUG: AAA802
• DRUG: Gallium (68Ga) gozetotide
• DRUG: Piflufolastat (18F)
• DRUG: Flotufolastat F 18
• DRUG: 18F-PSMA-1007

Sponsor

Novartis Pharmaceuticals